These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26774582)

  • 1. Molecular insights to the bioactive form of BV02, a reference inhibitor of 14-3-3σ protein-protein interactions.
    Valensin D; Cau Y; Calandro P; Vignaroli G; Dello Iacono L; Chiariello M; Mori M; Botta M
    Bioorg Med Chem Lett; 2016 Feb; 26(3):894-898. PubMed ID: 26774582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemically stable inhibitors of 14-3-3 protein-protein interactions derived from BV02.
    Iralde-Lorente L; Cau Y; Clementi L; Franci L; Tassone G; Valensin D; Mori M; Angelucci A; Chiariello M; Botta M
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):657-664. PubMed ID: 30727786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
    Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
    J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
    Modugno M; Casale E; Soncini C; Rosettani P; Colombo R; Lupi R; Rusconi L; Fancelli D; Carpinelli P; Cameron AD; Isacchi A; Moll J
    Cancer Res; 2007 Sep; 67(17):7987-90. PubMed ID: 17804707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3σ case.
    Corradi V; Mancini M; Santucci MA; Carlomagno T; Sanfelice D; Mori M; Vignaroli G; Falchi F; Manetti F; Radi M; Botta M
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6867-71. PubMed ID: 21962576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation for the amorphous state of ER-34122, a dual 5-lipoxygenase/cyclooxygenase inhibitor with poor aqueous solubility, in HPMC solid dispersion prepared by the solvent evaporation method.
    Kushida I; Gotoda M
    Drug Dev Ind Pharm; 2013 Oct; 39(10):1582-8. PubMed ID: 22519663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based assessment and network analysis of targeting 14-3-3 proteins in prostate cancer.
    Root A; Beizaei A; Ebhardt HA
    Mol Cancer; 2018 Oct; 17(1):156. PubMed ID: 30382885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revealing the binding modes and the unbinding of 14-3-3σ proteins and inhibitors by computational methods.
    Hu G; Cao Z; Xu S; Wang W; Wang J
    Sci Rep; 2015 Nov; 5():16481. PubMed ID: 26568041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition.
    Yosaatmadja Y; Patterson AV; Smaill JB; Squire CJ
    Acta Crystallogr D Biol Crystallogr; 2015 Mar; 71(Pt 3):525-33. PubMed ID: 25760602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first carborane triflates: synthesis and reactivity of 1-trifluoromethanesulfonylmethyl- and 1,2-bis(trifluoromethanesulfonylmethyl)-o-carborane.
    Kalinin VN; Rys EG; Tyutyunov AA; Starikova ZA; Korlyukov AA; Ol'shevskaya VA; Sung DD; Ponomaryov AB; Petrovskii PV; Hey-Hawkins E
    Dalton Trans; 2005 Mar; (5):903-8. PubMed ID: 15726143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecules modulation of 14-3-3 protein-protein interactions.
    Mori M; Vignaroli G; Botta M
    Drug Discov Today Technol; 2013 Dec; 10(4):e541-7. PubMed ID: 24451646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An optimised small-molecule stabiliser of the 14-3-3-PMA2 protein-protein interaction.
    Richter A; Rose R; Hedberg C; Waldmann H; Ottmann C
    Chemistry; 2012 May; 18(21):6520-7. PubMed ID: 22467351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.
    Mancini M; Leo E; Takemaru K; Campi V; Castagnetti F; Soverini S; De Benedittis C; Rosti G; Cavo M; Santucci MA; Martinelli G
    PLoS One; 2015; 10(7):e0131074. PubMed ID: 26147002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stabilization and inhibition of protein-protein interactions: the 14-3-3 case study.
    Milroy LG; Brunsveld L; Ottmann C
    ACS Chem Biol; 2013 Jan; 8(1):27-35. PubMed ID: 23210482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo determination of the crystal structure of a large drug molecule by crystal structure prediction-based powder NMR crystallography.
    Baias M; Dumez JN; Svensson PH; Schantz S; Day GM; Emsley L
    J Am Chem Soc; 2013 Nov; 135(46):17501-7. PubMed ID: 24168679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equimolar carbon absorption by potassium phthalimide and in situ catalytic conversion under mild conditions.
    Zhang S; Li YN; Zhang YW; He LN; Yu B; Song QW; Lang XD
    ChemSusChem; 2014 May; 7(5):1484-9. PubMed ID: 24677616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein-protein interactions as drug targets.
    Skwarczynska M; Ottmann C
    Future Med Chem; 2015; 7(16):2195-219. PubMed ID: 26510391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA.
    Zhao Z; Wisnoski DD; O'Brien JA; Lemaire W; Williams DL; Jacobson MA; Wittman M; Ha SN; Schaffhauser H; Sur C; Pettibone DJ; Duggan ME; Conn PJ; Hartman GD; Lindsley CW
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1386-91. PubMed ID: 17210250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical synthesis of phthalimides and benzamides by a multicomponent reaction involving arynes, isocyanides, and CO2/H2O.
    Kaicharla T; Thangaraj M; Biju AT
    Org Lett; 2014 Mar; 16(6):1728-31. PubMed ID: 24611430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
    Wang T; Banerjee D; Bohnert T; Chao J; Enyedy I; Fontenot J; Guertin K; Jones H; Lin EY; Marcotte D; Talreja T; Van Vloten K
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2985-90. PubMed ID: 26048789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.